市场调查报告书
商品编码
1218915
美国的D2C (消费者直接交易) 遗传基因检验市场 (2023年~2032年):市场规模 (各检验、技术、流通管道)、用途的潜在性、竞争市场占有率、预测U.S. Direct-to-Consumer Genetic Testing Market Size By Test, By Technology, By Distribution Channel, Industry Analysis Report, Application Potential, Competitive Market Share & Forecast, 2023 - 2032 |
美国的D2C (消费者直接交易) 遗传基因检验的市场,预计从2023年到2032年显示大幅度的成长。
遗传性疾病相关认识度的提高,提供个性化的健康资讯,增加健康积极性,廉价等,DTC遗传基因检验相关的几个优点,今后数年更加刺激其需求。
各技术中,标的分析的部门2022年显示5亿4,200万美元以上的规模。还有各销售管道上,预计从2023年到2032年OTC的部门提高大幅利益。
本报告提供美国的D2C (消费者直接交易) 遗传基因检验的市场调查,市场概要,市场成长的各种影响因素分析,法律规章、偿付环境,技术形势,市场规模的变化、预测,各种区分的明细,竞争环境,主要企业简介等彙整资讯。
U.S. Direct-to-Consumer (DTC) Genetic Testing Market is expected to demonstrate substantial growth from 2023 to 2032. DTC genetic testing offers people access to genetic information without involving a healthcare provider or health insurance company. Besides, several benefits associated with DTC genetics, such as promoting awareness regarding genetic diseases, offering personalized health information, making people more proactive about their health, and being less expensive, are anticipated to further stimulate its demand in the coming years.
In addition, the U.S. DTC genetic testing market is anticipated to increase owing to the growing prevalence of rare genetic diseases. Moreover, technological innovations in the healthcare industry are also anticipated to foster the demand for DTC genetic testing. The constantly growing investments made in the healthcare infrastructure in the U.S. and the high accuracy & efficiency possessed by DTC genetic tests will surge the demand and prove beneficial for industry growth over the foreseeable period.
Conglomerates working in the U.S. direct-to-consumer (DTC) industry are persistently taking strategic initiatives to gain a competitive advantage in the overall market. To cite an instance, in January 2021, myDNA merged with Gene by Gene and FamilyTreeDNA. The two businesses have amalgamated to become one of the leading global experts in genealogy, pharmacogenomic and nutrigenomic services. Besides, the merger is grounded on several shared beliefs about the tremendous potential of genetic information.
Overall, the U.S. direct-to-consumer (DTC) genetic testing industry is segmented in terms of test type, technology, and distribution channel.
Based on test type, the carrier testing segment is anticipated to experience robust growth through 2032, primarily due to the increasing cases of rare genetic diseases. Carrier testing determines if an individual carries a genetic variation (allele) related to a specific disease or trait. The landscape of rare diseases is constantly changing as new rare conditions or diseases are regularly identified and reported, which is anticipated to help the segment grow in the coming years.
By technology, the targeted analysis segment was valued at over USD 542 million in 2022. The targeted analysis determines the defects in genes that cause disorders. Besides, targeted genotyping empowers researchers to focus more on specific regions of interest, generates a smaller and more manageable dataset, reduces data analysis burden, and offers a cost-efficient solution with decreased turnaround time compared to broader approaches.
On the basis of distribution channel, over-the-counter segment is anticipated to amass considerable gains during 2023-2032. DTC genetic testing devices and drugs available over the counter enable people to self-treat without the need for prescription, while saving health systems valuable resources and consumers' money and time.